China Cinda Asset Management Co Ltd operates within the Life insurance sector.
In addition to historical fundamental analyses, the complete report available to purchase compares China Cinda Asset Management Co Ltd with three other
insurance companies in Asia:
Hubei Biocause Pharmaceutical Co., Ltd.
sales of 50.19 billion Chinese Renmimbi [US$7.37 billion]
of which 95%
China Life Insurance Company Limited
(329.16 billion Taiwanese Dollars [US$11.29 billion]
of which 100%
was Insurance & Related Activities), and
Korean Reinsurance Company
based in KOREA (SOUTH)
(10.46 trillion Korean Won [US$8.93 billion]
During the year ended December of 2019, sales at
China Cinda Asset Management Co Ltd were HK$74.49 billion (US$9.61 billion).
decrease of 18.3%
versus 2018, when the company's sales were HK$91.13 billion.
Contributing to the drop in overall sales was the 28.0% decline
in Financial Services, from HK$34.78 billion to HK$25.03 billion.
However, these declines were partially offset by the increase in sales of
Distressed Asset Management (up 62.0% to HK$85.90 billion)